New hope for chinese patients with Hard-to-Treat chronic GVHD

NCT ID NCT06824103

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGVHD) that did not improve with steroids. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The main goal is to see if ruxolitinib can help control the disease by reducing symptoms without needing other treatments. The study involves 50 participants and will monitor safety and effectiveness over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Nanning, Guangxi, 530021, China
Novartis Investigative Site
RECRUITING

Guiyang, Guizhou, 550004, China
Novartis Investigative Site
RECRUITING

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site
RECRUITING

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Changsha, 410000, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Wujiang Nongchang, 065201, China

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VS. HOST DISEASE CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE GRAFT-VS-HOST DISEASE